RxDoctor Payments Data

Kimberly Loe

Family · Flowood, MSNPI 1881928315

Payments from drug & device makers

$5,375in general payments, 2019–2025

Across 240 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Axonics, Inc.$917
  • Astellas Pharma US Inc$550
  • Bayer$515
  • Sumitomo Pharma America, Inc.$406
  • Dendreon Pharmaceuticals LLC$261
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$71913%
  • Food & beverage$4,23479%
  • Education$4228%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,375 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$407,541
Medicare patients
605
Services billed
13,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron94$61,720
MyrbetriqMirabegron67$41,480
ErtapenemErtapenem Sodium80$36,734
Methenamine Hippurate183$10,845
Estradiol112$7,583
Tamsulosin Hcl545$6,906
Tolterodine Tartrate ErTolterodine Tartrate85$6,829
Solifenacin Succinate124$3,756
Dutasteride111$3,084
Bethanechol Chloride51$2,348
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst87$2,168
Meropenem15$2,044
Potassium Citrate ErPotassium Citrate27$1,650
Doxycycline Hyclate125$1,300
Ciprofloxacin Hcl173$1,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$406$61,72094 claims
Astellas Pharma US IncMyrbetriq$550$41,48067 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.

Other family in Flowood

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →